About the Disease
Type 1 Diabetes (T1D) is an autoimmune condition in which the body’s immune system attacks the insulin-producing beta cells in the pancreas. This leads to little or no insulin production, requiring lifelong insulin injections or pumps. Stem cell therapy is being studied as a way to replace or regenerate these cells, potentially reducing or eliminating the need for external insulin.
Institutes Offering Stem Cell Therapy for Type 1 Diabetes:
- Abu Dhabi Stem Cells Center (ADSCC) – Abu Dhabi, UAE
- Offers mesenchymal stem cell (UC-MSC) therapy for managing Type 1 Diabetes.
- Reported successful results in a young patient with promising outcomes.
- Website: adscc.ae
- King’s College Hospital / King’s Health Partners – London, UK
- Conducting research with stem-cell derived pancreas islets to replace damaged beta cells.
- Part of an advanced clinical trial setting.
- Website: kingshealthpartners.org
- Medical University of South Carolina (MUSC) – Charleston, South Carolina, USA
- Running a clinical trial with umbilical cord–derived stem cells to test safety and effectiveness in T1D.
- Contact: Leah Benn, MPH – bennle@musc.edu
- Trial info: Clinical Trial Link
- First Hospital of Hebei Medical University / Partner Hospitals – China
- Conducting “Stem Cell Educator” trials using cord-blood derived stem cells (CB-SC) to retrain the immune system in T1D patients.
- Registered Clinical Trial: NCT01350219
- Hospital Universitario Central de Asturias – Oviedo, Spain
- Also part of the Stem Cell Educator trial network for T1D.
- Website / info via: Clinical Trial Registry
- University of Pennsylvania – Center for Transplant Science and Innovation – Philadelphia, USA
- Developing stem-cell derived functional islets for future clinical use.
- Pioneers in islet transplantation research aiming to reduce insulin dependence.
- Website: med.upenn.edu
